Statement Of Cash Flows [Abstract]

BioArctic - Filing #5863029

Concept 2024-01-01 to
2024-12-31
As at
2024-12-31
As at
2024-01-01
2023-01-01 to
2023-12-31
As at
2023-12-31
As at
2023-01-01
Statement of cash flows [abstract]
Cash flows from (used in) operating activities [abstract]
Profit (loss)
228 515 SEK
252 640 SEK
Adjustments to reconcile profit (loss) [abstract]
Adjustments for decrease (increase) in other operating receivables
105 225 SEK
11 979 SEK
Adjustments for increase (decrease) in other operating payables
42 655 SEK
25 132 SEK
Other adjustments for non-cash items
57 383 SEK
9 895 SEK
Cash flows from (used in) operations
316 332 SEK
309 694 SEK
Interest paid, classified as operating activities
1 849 SEK
379,000 SEK
Interest received, classified as operating activities
34 505 SEK
34 228 SEK
Cash flows from (used in) investing activities [abstract]
Purchase of property, plant and equipment, classified as investing activities
26 635 SEK
7 443 SEK
Other inflows (outflows) of cash, classified as investing activities
232 267 SEK
500 042 SEK
Cash flows from (used in) investing activities
205 633 SEK
507 485 SEK
Cash flows from (used in) financing activities [abstract]
Payments of lease liabilities, classified as financing activities
329,000 SEK
917,000 SEK
Dividends paid, classified as financing activities
6 016 SEK
14 982 SEK
Cash flows from (used in) financing activities
5 686 SEK
14 064 SEK
Increase (decrease) in cash and cash equivalents before effect of exchange rate changes
105 013 SEK
183 727 SEK
Effect of exchange rate changes on cash and cash equivalents [abstract]
Effect of exchange rate changes on cash and cash equivalents
6 374 SEK
10 093 SEK
Cash and cash equivalents
512 927 SEK
611 567 SEK
611 567 SEK
805 386 SEK

Talk to a Data Expert

Have a question? We'll get back to you promptly.